Nozomi Oda is a partner of our registered associated offices of Ito & Mitomi. Nozomi’s practice focuses on cross-border public and private M&A, joint ventures, strategic investments, and capital markets transactions. She has a particular emphasis on advising private equity and life sciences clients.

Nozomi also regularly advises on a wide range of Japanese regulations, including securities, financial, and fund regulations, merger review, and healthcare and life sciences regulations. In addition to her work in private practice, Nozomi previously spent two years with Japan’s Financial Services Agency (FSA) as a deputy director of the corporate disclosure department, where she participated in the drafting of the FSA’s regulations on disclosures regarding private placement offerings and director compensation.

Nozomi is a bengoshi admitted to practice in Japan and New York, and is a member of the Daiichi Tokyo Bar Association.

Nozomi’s experience includes representing:

  • Daiichi Sankyo in its $6.9 billion global drug development and commercialization agreement with AstraZeneca.
  • C.R. Bard in its acquisition of Medicon, a Japan-based distributor of medical equipment.
  • Nissan Motor in its $2.3 billion acquisition of a 34% stake in Mitsubishi Motors.
  • Starbucks Coffee in its buyout of the remaining 60.5% share of Starbucks Coffee Japan.
Show More
Close

Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.